Problem Coronary heart disease
Format Double-blinded multi-center RCT
Treatment Rosuvastatin (40mg)
Control Atorvastatin (80mg)
Population 1039 patients
Inclusion criteria Patients 18 to 75 years of age were eligible if they had at least one vessel with 20% stenosis on clinically indicated coronary angiography and a target vessel for imaging with less than 50% obstruction. Patients who had not been treated with a statin in the preceding 4 weeks were required to have an LDL cholesterol level at entry that was higher than 100 mg per deciliter (2.6 mmol per liter); those who had received such treatment were required to have a level higher than 80 mg per deciliter (2.1 mmol per liter).
Exclusion criteria History of intensive lipid-lowering therapy for more than 3 months in the previous year
Uncontrolled hypertension, heart failure, renal dysfunction, or liver disease
Follow-up 104 weeks
Primary endpoint Percent atheroma volume (PAV), decreased by 0.99%
Secondary endpoint(s) Normalized total atheroma volume (TAV)
Details .
Brief summary: Rosuvastatin gave better LDL/HDL than atorva, but atheromata unchanged
PAPER: Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Date 1 Dec 2011
Journal N Engl J Med. 2011 Dec 1;365(22):2078-87
Information Rosuvastatin 40mg vs. Atorvastatin 80mg:
-Reduced level LDL
-Higher level of HDL cholesterol
-BUT Similar degree of regression of PAV

-Higher alanine aminotransferase in atorvastatin group
-Higher proteinuria in rosuvastatin
-No difference in HbA1c